Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 15/20 | 0.57 |
| ▸ | KLK2 | P20151 | 2/20 | 0.51 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 1/20 | 0.51 |
| ▸ | F11 | P03951 | 1/20 | 0.51 |
| ▸ | KLK1 | P06870 | 1/20 | 0.51 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.51 |
| ▸ | KLK13 | Q9UKR3 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | CTSG | P08311 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23104993 | 0.92 | PLAU (0.68) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL22256705 | 0.89 | PLAU (0.68) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL23104952 | 0.84 | KLKB1 (0.59) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL22341394 | 0.71 | ITGB3 (0.70) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL14082355 | 0.70 | MC4R (0.58) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL30883996 | 0.70 | ITGAV (0.74) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL29540118 | 0.70 | ITGAV (0.74) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL9908255 | 0.69 | MC4R (0.57) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL29540413 | 0.69 | ITGAV (0.67) | PLAUITGB3ITGB1ITGAVITGA5 | |
| SCHEMBL29540230 | 0.69 | ITGAV (0.69) | PLAUITGB3ITGB1ITGAVITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | Bicyclerd Limited (GB) | 2023-09-05 | — | — | US | disclosed |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | Bicyclerd Limited (GB) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746126-B2 | Bicyclic peptide ligands with detectable moieties and uses thereof | VIP, NGLY1, GRPR | PLAU 719/4885ITGB3 2734/4885ITGB1 4079/4885 |
| US-20210079045-A1 | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE MOIETIES AND USES THEREOF | VIP, NGLY1, GRPR | PLAU 719/4885ITGB3 2734/4885ITGB1 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.